Multiple Myeloma News and Research

RSS

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

Scientists Discover New Class of Molecular Glue Degraders for Cancer Therapy

Cells contain molecular machinery that targets and disposes of unwanted proteins to maintain homeostasis.

17 Nov 2023

New Insights Into Tumor-Immune Interactions Could Lead to More Effective Therapies for Multiple Myeloma

A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.

10 Nov 2023

Thermo Fisher Scientific Announces the Launch of the EXENT® Solution with IVDR Certification

Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification.

28 Aug 2023

Scientists Uncover New Mechanism for Degrading Short-Lived Proteins

Short-lived proteins control gene expression in cells to carry out a number of vital tasks, from helping the brain form connections to helping the body mount an immune defense. These proteins are made in the nucleus and are quickly destroyed once they've done their job.

25 Aug 2023

High-Throughput Screening of Existing Drugs to Fight Multiple Myeloma More Effectively

Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells.

28 Apr 2023

Understanding the relationship between gut microbiome and CAR T-cell therapy response

Microorganisms live in or on almost every part of the human body and play an important role in the regulation of normal human processes. As a result, changes in the number or type of microorganisms, also known as the microbiome, can contribute to disease and altered responses to therapy, including cancer treatment.

14 Mar 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

17 Feb 2023

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.

31 Jan 2023

Researchers find immune-effective ways to destroy cancer cells

Treatment with chimeric antigen receptor T cells (CAR T cells) is often the last hope for patients with lymphoma, multiple myeloma, or certain kinds of leukemia.

26 Jul 2022

Researchers discover a new interferon-gamma receptor signaling pathway

The interferon-gamma receptor (IFNgR) signaling pathway has been identified to be crucial for the vulnerability of glioblastoma tumors to death by CAR T-cell immunotherapy, according to researchers at Massachusetts General Hospital (MGH).

10 Jun 2022

Study shows new potential target for CAR T cells to inhibit solid tumors

CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.

10 May 2022

Yale researchers find a way to 'supercharge' tumor-attacking T cells

Yale scientists have identified a way to "supercharge" tumor-attacking T cells, a finding that may not only improve the effectiveness of a promising type of cell-based cancer immunotherapy but also expand the number of cancers it can treat.

11 Mar 2022

Leukemia-on-a-chip; The Future of Preventing Therapy Resistance?

We speak to Dr. Chao Ma, one of the speakers at SLAS 2022, about his groundbreaking 'leukemia-on-a-chip' technology and its future within therapy resistance.

From Society for Laboratory Automation and Screening (SLAS) 27 Jan 2022

Mayo Clinic researchers examine potential new CAR-T cell treatment for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma.

28 Jun 2021

Study identifies new epigenetic control pathways in multiple myeloma growth

An international group of researchers from Japan, the United States, and the UK studied the role of the histone demethylase KDM5A in multiple myeloma.

18 May 2021

Low representation of minority groups in genomic databases may impact therapy selection

Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.

22 Mar 2021

Genome architectural changes linked to B cell-related blood cancers

Flaws in the way chromosomes are packed into antibody-producing B-cells seem to play a key role in the development of B-cell-related blood cancers.

2 Feb 2021

Two enzymes drive pre-cancer stem cells into malignancy

Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many different specialized cell types, they play an important role in our development and health.

From UC San Diego 27 Jan 2021

Investigational antisense medicine lowers disease burden, reduces myeloma cell abundance in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

From UC San Diego 21 Jan 2021

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.

7 Jan 2021